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E
ponyms are a long-standing tradition in medicine.
Eponyms usually involve honoring a prominent
physician scientist who played a major role in the
identification of the disease. Under the right circum-
stances, a disease becomes well known through the name
of this individual. It is often easier to remember a disease
by its eponym than by the more scientific pathologic
description; for example, which name is better known,
Hodgkins disease or any of its five types, to wit, nodular
sclerosing, mixed cellularity, lymphocyte depleted, lym-
phocyte rich, and nodular lymphocyte-predominant?
The naming process usually beginswhen popular atten-
tion is drawn to an entity, not necessarily for the first
time. In fact, the physician scientist whose name becomes
the eponym is often distinguishable from other parallel
observers for reasons other than being first. It may be
the individual’s reputation, standing, accuracy, details
contained in the report or publication, or a fortuitous
rediscoveryoften decades later by someone who then asso-
ciates the disease with one or more of the earlier physi-
cian scientists. Sometimes luck plays a major role. There
are no rules on eponym development. It may take an
extraordinary period of time, be different in different
languages and cultures, and evolve as more is known
about the physician or the disease.
How many medical eponyms are there? There are
medical eponyms for physical signs, tendons, reflexes,
palsies, cysts, choreas, aneurisms, contractures, and many
others. Some have estimated more than 8,000 (1). There
are single name eponyms and multiple individual epo-
nyms. There are possessive and non-possessive forms (2).
When there are multiple names to the eponym, it is often
interesting to assess how the order was adopted. It may be
individual prestige, departmental seniority and, no doubt,
could involve some bullying. Or it may be as simple as
drawing straws or the famous WatsonCrick coin flip 
won by Watson.
Eponyms can take decades to be commonly accepted,
which is not necessarily a bad thing. Many eponyms have
been identified after the death of the eponym name-
sake, when rediscovered by a secondary investigator who
posthumously connects it with the individual who ‘wrote
it up’. Eponyms often reflect the dominance of scientific
cultures and languages at the time. Eponyms flourished
from the late 19th to early 20th centuries when the lead-
ing scientific languages were English and German. A
good example of the eponym process is the entity of acute
adrenal failure secondary to meningococcemia, referred
to as adrenal apoplexy. Numerous case reports of this
entity were published around 1900 mostly in obscure
medical journals following autopsies that revealed adrenal
(or ‘suprarenal’) fatal hemorrhage complicating sepsis
(3). In 1911, British physician Rupert Waterhouse pub-
lished in Lancet, the leading English language journal at
the time, a fulminant fatal case report (4). In 1917 and
1918, Carl Friderichsen published two cases and a review
of the literature in Danish and German (5). In 1933,
Eduard Glanzmann, in a clinical review, gave it the name
of WaterhouseFriderichsen syndrome (6).
In the remainder of this perspective, we will review
10 eponymous medical diseases or syndromes. I believe
eight are here to stay. The last name alone suffices, often
not needing a word-like syndrome or disease to clarify.
Two others are famous, if not infamous, and not only are
#Robert P. Ferguson, has had no part in the review and decision process of this paper.
JOURNAL OF COMMUNITY HOSPITAL
INTERNAL MEDICINE PERSPECTIVES
Journal of Community Hospital Internal Medicine Perspectives 2014. # 2014 Robert P. Ferguson and Deborah Thomas. This is an Open Access article
distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/),
permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
1
Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25046 - http://dx.doi.org/10.3402/jchimp.v4.25046
(page number not for citation purpose)fading away but there are active campaigns to erase them
from memory, demonstrating that the slow approach may
be the wise way to go, not unlike the rule that a player is
not eligible to be elected to the Baseball Hall of Fame
until 5 years after retirement.
James Parkinson was born in London
in 1755. His initial professional inter-
ests were primarily in politics. He was
an anti-Pitt government activist and
was even questioned as part of the
investigation of a rumored conspiracy
to assassinate King George III after
America was victorious in its war of independence. After
turning to medicine, he became known for his obser-
vational skills and clarity of writing style. In 1817, he
published an ‘Essay on the Shaking Palsy’, described as
‘paralysis agitans’ (7). Parkinson was 62 when he pub-
lished this paper. He would die 7 years later. Approxima-
tely 60 years elapsed before famous French pathologists
Charcot and Trousseu (themselves eponym namesakes)
attached Parkinson’s name to the condition (8).
Thomas Hodgkins was born a Quaker
in England in 1798. Not surprisingly,
he developed strong opinions as an
adult against servitude and slavery.
As a physician at Guys Hospital in
London, he was a contemporary of
Thomas Addison and Richard Bright.
Guys Hospital was the epicenter of eponyms. Hodgkins
was fortunate at least twice in the development of the
Hodgkins eponym. His original descriptive paper was pub-
lished in 1832 (9). Read and referred to by his colleague,
Richard Bright, he published these reviews in 1838, but
did not become widely known. In 1856, Samuel Wilkes
reported similar lymphadenopathy and splenomegaly,
initially believing he had identified something new (10).
Wilkes, before publishing, discovered Bright’s reference to
Hodgkins’ findings. The best he could say was that he re-
discovered what Hodgkins had discovered 27 years before.
Robert James Graves was born in 1796
in Dublin. He was known as a polyglot
as well as a physician. As a physician,
he was considered a great teacher and
contributed to the fame of the Dublin
School of Medicine. For years physi-
cians had been aware of the association between goiter,
heart disease, and tachycardia. This was widely known in
both the leading German- and English-speaking medical
communities. Graves’ original description in 1835, when he
presented to the London Medical Society, was the first to
describe exopthalmus as part of this condition (11). His
associations paralleled those of Carl Basedow in Germany.
Even today the eponym may vary depending on the
native language. Graves continued his skillful lectures for
many years and that helped to establish the eponym.
Alois Alzheimer was a Bavarian, born
in 1864. He became a pathologist and
a psychiatrist. He began observing a
patient at the Frankfort Asylum for
Lunatics and Epileptics in 1901. When
the patient died in 1906, Alzheimer dis-
sected the brain and, augmented by the newly developed
silver stains, identified amyloid plaques and neurofibril-
lary tangles. He presented his findings the same year. The
dementia became known after him when his discoveries
were written in Kraepelin’s German textbook, considered
the standard of its time (12).
Hakaru Hashimoto was born in Japan
and graduated from Kyushu University
Medical School in 1907. As a young
man he moved to Germany to continue
his career. In 1912, he published ‘A
Report on Lymphomatus Goiter’ (13).
Years later the specimens were reviewed by American and
British researchers who named the disease as Hashimoto’s
disease (14). Hashimoto returned home in 1916 because
of World War I and became the town doctor in his
hometown before succumbing to typhoid at the age of
53 in 1934.
Harvey Cushing was born in Cleveland in
1869. He received his medical education
and training at Harvard, Johns Hopkins,
and in Europe. He was a leading neuro-
surgeon of his day. He was a close asso-
ciate of William Osler of Hopkins. In
1912, he reported a condition that he
referred to as ‘polyglandular syndrome’
related to a pituitary disorder. His scientific career was
interrupted by events in Europe. When the US became
involved in World War I, he served with the US Expedi-
tionary Force and practiced neurosurgery near the front
lines. He treated Lt. Edward Revere Osler (Osler’s son),
who died of his wounds at the third battle of Ypres. In
1925, Cushing received a Pulitzer Prize for his biography
of William Osler.
In 1932, he published his pituitary observations, dis-
covering basophilic adenoma of the pituitary, which be-
came known as Cushing’s disease (15). Despite doubters,
his findings and hypothesis were vindicated over time.
Burrill Crohn was born in Manhattan in
1884 and became a prominent New York
City gastroenterologist. He was chief of gas-
troenterology at Mount Sinai Hospital in
1920. He and his colleagues identified a
cohort of patients that had similar clinical
manifestations not previously identified. Crohn, with Leon
Ginzburg and Gordon Oppenheimer published ‘Regional
Ileitis: a Pathological and Clinical Entity’ (16). Why Crohn
was the first of the three potential lead authors, is unclear
(whether by serendipity or simply by the alphabet); and
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descriptiveness of ‘regional enteritis’, was why there was
an eponym. Moreover, Crohn reportedly was unhappy
with the eponym. Or, perhaps he protested too much.
Burrill Crohn practiced until the age of 90. He died in
1983 at 99, half a century after his landmark paper.
As noted above, I believe that these eponyms are here
to stay. The remainder are, for the reasons discussed
below, not likely to remain in common usage.
Hans Reiter was born near Leipzig in
1881. He studied medicine in Berlin,
Paris, and London. During World War
I, he observed non-gonococcal urethiritis/
arthritis in a soldier. This and other cases
described by Reiter led to a syndrome
named for him (17). After World War I,
he became an admirer of the rising political star, Adolf
Hitler, and joined the Nazi party. In World War II, he
became a high-ranking physician staff member and parti-
cipated in criminal experimentation in prisoners, such
as at the concentration camp at Buchenwald. After
the war, Reiter was tried at Nuremberg and interned by
the Russians and Americans. Eventually, he was released.
Post-war, Reiter’s syndrome became an accepted eponym
of a clinical entity. However, when Reiter’s wartime acti-
vities were rediscovered a campaign was initiated to dis-
associate his name from reactive arthritis (18).
Friederich Wegener was born in Germany
in 1907. He developed into a brilliant phy-
sician and pathologist. Working in Breslau,
he first described a new type of upper air-
ways granulomatous destructive airway
disease. He published cases in the German
literature in 1939 (19). After World War II, a Swedish
pathologist recognized it as a new disease discovered by
Wegener, and named it for him. Because of Wegener’s
accomplishments, he was honored as a Master Clinician
by the ACCP in 1989. However, in 2000, while researching
a paper on Wegener, Matteson, and Woywoldt uncovered
Wegener’s Nazi past involving medical experiments con-
ducted near Lodz, Poland, as well as, his membership in
the SA and possible involvement in the genocide which
took place in Poland during the war (20). The details
of his involvement in Nazi atrocities were not as well
documented as those of Reiter, but it seemed clear that he
must have at least been aware of what was happening
in Poland at that time. In 2002, a campaign was initiated
to change the name of the disease to ANCA associated
granulomatous vasculitis, and, later to granulomatosis
with polyangitis. How successful this campaign has been
is arguable, since in many instances the use of one of these
tongue twisting terms is followed by ‘meaning Wegener’s.’
It is not that easy to eliminate an eponym by a generation
used to using it.
Thus we see in these two cases, one of the problems
with eponyms is that subsequent information may reveal
personal issues that are inconsistent with the honorary
component attached to naming a clinical entity after
an individual. As Germany was one of the centers of
science in the first half of the twentieth century, it is not
surprising that instances of brilliant discovery took place
in that country. However, this was also the period of
ghastly crimes committed in the treatment of individuals
by representatives of that nation in Europe.
Munchausen’s syndrome, or, factitious dis-
order, is, without a doubt a favorite medical
eponym. While Munchausen was a histor-
ical figure  Hieronymus Carl Friedrich
Baron von Munchausen  the good Baron
Munchausen had nothing to do with dis-
covery or description of the eponymous syndrome. He
was born in Germany in 1720 to a prominent family in
the nobility. He became a soldier for hire and fought in a
number of military campaigns. After he retired, he
became well known for entertaining at dinner parties
on his estate. He liked to tell tall tales of his military
adventures, often with fanciful entertaining exaggeration.
Many of these tales were extensions of local folk tales,
centuries old. In 1785, an anonymous publication of the
tales with illustrations appeared that was unauthorized
(21). The Baron was annoyed at the embarrassing use of
his noble family name. Despite his efforts to suppress the
series, the publications continued and became popular
throughout Europe.
Richard Asher published a case series of factitious
disorders in 1951 (22). He stated: ‘Like the famous Baron
von Munchausen, the persons affected have always travel-
led widely, and their stories, like those attributed to
him, are both dramatic and untrue.’ Even though it was
a century and a half after the baron’s death, the name
stuck!
Conclusion
Typically, eponyms were established decades or even
centuries ago and were named for individuals who were
credited first with identification, description, and pub-
lication. Many of the names were fortuitously connec-
ted decades later as they were rediscovered by others.
Although there have been instances where eponyms were
later discarded, the survivors are by and large written in
stone. Although the medical disease eponym is an archaic
concept and may lead to scientific confusion, we believe
that eponyms are here for the foreseeable future.
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